Alliance for Health Logistics Systems

Characterization of the Supply Chains for Medicines and Medical Supplies in Latin America

January 2015







Decades of technical assistance to improve medicine supply chains in Latin America have left experiences, methodologies, and tools that are not being sufficiently shared among countries to strengthen the knowledge of decision makers who are undertaking reforms in their supply systems. The Alliance for Health Logistics Systems in Latin America (Alianza para Sistemas Logísticos en Salud de América Latina, or ASLAL) has the objective of promoting more efficient management of medicine supply chains in the region. The partners that make up the Alliance hope to contribute to filling this void by sharing, in a cost-effective manner, knowledge that is already available and ongoing experiences.









Inspired Leadership. Sound Management. Transparent Governance.

This document was prepared by Edgar Barilllas (Portfolio Manager USAID/SIAPS), Nadia Olson (Senior Technical Advisor USAID/Deliver), Anabella Sanchez (Regional Manager USAID/Deliver), and Nora Quezada (Regional Director USAID/Deliver). The content of this document corresponds to the referenced agencies and does not necessarily reflect the points of view of the US Agency for International Development or the US Government.

CONTENTS

Acronyms and Abbreviations	iv
Background	1
Methodology	
Results	
Analysis and Discussion	
Annex 1. Data Collection Instrument	16

ACRONYMS AND ABBREVIATIONS

ASLAL Alliance for Health Logistics Systems in Latin America

(Alianza para Sistemas Logísticos en Salud en América Latina)

DCP disease control program

UNGSM National Pharmaceutical Supply Management Unit

(Unidad Nacional de Gestión de Suministro de Medicamentos)

BACKGROUND

In the region of the Americas different modes of organization are used for medicine supply chains. Some are in the process of transformation as a product of sectoral reforms or decentralization of public administration. However, until now no systematic characterization of the supply chains has been made based on standardized categories. In the absence of this information, the decision makers responsible for the transformations in these countries find themselves without tools for recognizing and comparing the base situation and recording the implications of the changes.

This rapid study, coordinated by the Alliance for Health Logistics Systems in Latin America (Alianza para Sistemas Logísticos en Salud en América Latina, or ASLAL), starts from a taxonomic proposal agreed upon by its members for the purpose of characterizing the medicine supply chains in the Americas based on standardized categories.

METHODOLOGY

In the absence of methodologies that characterize medicine supply chains in a systematic and comparable manner, representatives from different member institutions of ASLAL agreed upon the categories, variables, and operative definitions that are presented in figure 1 and annex 1. The achieved consensus was based on available definitions in literature on the subject 1 and the experience of expert consultants in medicine supply.

It was agreed that the characterization of a supply chain should include two components:

- The organizational and operative characteristics that identify it: The institutional affiliation, the concentration or deconcentration of its functions, the integration or *verticality* of supply, the center-periphery model of distribution, and the level of regulation by the State
- The results that they obtain: The information the system produces for supporting decision making, the availability of medicines at the end of the chain, and the cost of logistics operation contrasted with reference information²

The agreed upon categories and operative definitions were organized in a data collection instrument (annex 1) that would allow the informants to mark the option that best characterizes the medicine supply chain in their country. In some categories, such as *mixed* concentration of functions and *mixed* integration, informants were asked to specify the components of the supply chain as centralized or decentralized, and integrated or vertical, respectively.

² John Snow Inc. Getting products to people: the JSI framework for integrated supply chain management in public health. Arlington, VA: John Snow Inc.; 2012 Jan.

¹ Management Sciences for Health. MDS-3: managing access to medicines and health technologies. 3rd ed. Arlington, VA; Management Sciences for Health; 2012. 1,088 p.




Figure 1. Categories and variables agreed upon for the characterization of medicine supply chains in Latin America

The forms were completed by the coordinators of the national medicine supply management units (unidades nacionales de gestión de suministro medicamentos, or UNGSM) of the ministries of health (or their equivalent), or by members of the Alliance with knowledge of the supply chain of a particular country. In this second case, the information obtained was checked with and validated by the coordinator of the UNGSM.

The information from the 11 countries was collected between August and October 2014.³. None of the informants objected to the methodology nor the suitability of the categories and definitions agreed upon.

³ The countries are Bolivia, Brazil, Colombia, the Dominican Republic, El Salvador, Guatemala, Honduras, Mexico, Nicaragua, Panama, and Peru.

RESULTS

The 11 forms received include information from Meso-American (El Salvador, Guatemala, Honduras, Mexico, Nicaragua, and Panama), Caribbean (Dominican Republic), and South American (Bolivia, Colombia, and Peru) countries.

Several of the countries included in the sample group were in the process of transforming their supply chains (Dominican Republic, Guatemala, Honduras, and Panama). The proposed changes were in the planning phase or early phases of implementation. The consolidated results, therefore, reflect the situation at the moment the information was gathered (August to October 2014) and not the desired outcome.

Figure 2 presents the observed situation. Each bar represents the percentage of countries that exhibit a particular characteristic in their supply chain.




Figure 2. Profile of medicine supply chains in Latin America (%, n = 11)

Thus, and with the limitations imposed by the sample size and a methodology that is being tested for the first time, it is possible to characterize, as tendencies, the medicine supply chains in the Americas in the following form:

• Managed by public operators: In most of the countries (9 of 11), the operators of the supply chain are State institutions (table 1). The two countries that reported private participation (Colombia and Dominican Republic) began sectoral reforms several years ago that promote free competition in the allocation of resources and/or transferring the decision to contract third parties to decentralized, autonomous bodies.

Table 1. Operators

Public operators	All or most of the supply chain operators are State institutions.
	Bolivia, Brazil, El Salvador, Guatemala, Honduras, Mexico, Nicaragua, Panama, Peru
Private operators	Although funding is public, all or most operators are private, contracted agents.
	None
Mixed	Public operators are responsible for some functions (storage, for example), whereas other private operators are responsible for others.
	Colombia, Dominican Republic
Private pharmacy	All of the medicines financed by private insurance are commercialized by private operators and dispensed from private pharmacies.
	None

• Combined centralized and decentralized functions (mixed): Only Bolivia has a completely decentralized supply chain. The rest have decentralized some components (in particular, transport from the department/region to the facilities) and maintained others as centralized (in particular, quality control). With the exception of Nicaragua, in most of the countries and for most of the components in the supply chain, a combination of centralized and decentralized functions exists. This *mix* is fundamentally dependent upon the type of product: the medicines and supplies for disease control programs (DCP; for example, tuberculosis, HIV/AIDS, malaria) are programmed, acquired, and distributed at the central level, meanwhile the rest of the medicines and supplies for noncommunicable conditions and pathologies are managed in a decentralized manner.

Table 2. Centralization or Decentralization of Function

Centralized	The central level coordinates purchases, customs clearance and storage, and transport to the periphery (region or department).
	Nicaragua, Panama
Descentralized	Purchases, storage, and distribution to health facilities are responsibilities of the departmental/regional level.
	Bolivia
Mixed	Purchases can be centralized, but the shipment is direct to the regions/departments, from where it is distributed to health facilities.
	Brazil, Colombia, Dominican Republic, El Salvador, Guatemala, Honduras, Mexico, Panama, Peru

Table 3. Characterization of the Deconcentration of Functions

Functions	:	Brazii) (1)	Colonibla	71 C 2150		0,000,000	Guatemala	11	nondulas	Monigo	Mexico	ć	reru	Dominican	Republic
	С	D	С	D	С	D	С	D	С	D	С	D	С	D	С	D
Programming																
Purchase																
Quality control																
Storage																
Responsibility for transport (center to department/region)																
Responsibility for transport to facilities																

Note: C = centralized; D = decentralized.

• **Integrated**: Six of the 11 countries (Bolivia, Brazil, Colombia, Nicaragua, Panama, and Peru) declared that the medicines and supplies for DCP and for (chronic) communicable diseases use the same mechanisms for storage, inventory management, and transport. In four (Dominican Republic, El Salvador, Guatemala, and Honduras), the system was classified as *mixed*, given that although the tendency is toward integration, some functions (particularly programming and purchasing) are still the responsibility of the DCPs and not of the UNGSMs. In the processes of integration, the functions integrated early on are storage and transport.

Table 4. Integration

Integrated	Medicines and supplies for disease control programs (TB, HIV) and (chronic) noncommunicable pathologies use the same mechanisms of storage, inventory management, and transport.				
	Bolivia, Brazil, Colombia, Nicaragua, Panama, Peru				
Vertical	Medicines and supplies for disease control programs (TB, HIV) and (chronic) noncommunicable pathologies use different mechanisms of storage, inventory management, and transport.				
	Mexico				
Mixed	Some disease control programs have been integrated into a single system, whereas others keep their own warehouses, inventory management, and transport.				
	Dominican Republic, El Salvador, Guatemala, Honduras				

Table 5. Characterization of the Integration of Functions

Functions	El Salvador		Guatemala		Honduras		Dominican Republic	
	I	V	I	V	I	V	I	V
Programming								
Purchase								
Quality control								
Storage								
Responsibility of transport (center to department/region)								
Responsibility for transport to facilities								

Note: I = integrated; V = vertical.

• Distribution model from a central medical warehouse: In six countries, particularly those that are geographically small and without federal organization (Dominican Republic, El Salvador, Guatemala, Honduras, Nicaragua, and Panama), the medicines are distributed from one or various central warehouses, under the administration of the public sector. In these countries, the regional warehouses or facilities usually "collect" medicines from the central warehouse because of a lack of an organized system of "delivery." In federal countries of greater geographic size (Bolivia, Colombia, Mexico), the products are acquired directly by decentralized bodies and transported to their warehouses by the commercial provider. In three countries (Brazil, Dominican Republic, and Peru), primary parastatal distributors at the central level carry out functions of acquisition, warehousing, and distribution, particularly for products used for DCPs.

Table 6. Distribution

Direct delivery or purchase	The products are bought at the regional, district, municipal, or other lower levels, and the products are collected by lower levels or delivered to regional, district, or municipal warehouses under the administration of the public sector.
	Boliva, Colombia, Guatemala, Mexico, Peru
Primary distributor	The medicines and supplies are watched over by and distributed from one or various central or peripheral warehouses under administration of a private operator contracted by the public sector.
	Brazil, Dominican Republic, Peru
Central medicines warehouse	The medicines and supplies are watched over by and distributed from one or various central warehouses, under administration of the public sector, from which transport to the periphery is coordinated.
	Dominican Republic, El Salvador, Guatemala, Honduras, Nicaragua, Panama

• Medium level of regulation: Seven of the 11 countries (Bolivia, Dominican Republic, El Salvador, Guatemala, Honduras, Mexico, and Panama) reported a medium level of regulation. In these countries, policies, laws, and standards exist that regulate the supply of medicines, but they are not observed because of a lack of public institutionalization. The responsible departments or units, for example, are not provided with the resources to complete these functions. In the four remaining countries (Brazil, Colombia, Nicaragua, and Peru), a high level of regulation was reported.

Table 7. Regulation

High	Policies, laws, and standards exist that regulate the supply of medicines. For example, price controls, facility certifications, and standardized procedures for the management of supplies exist, and they are observed. Public institutions (departments, units) are provided with the resources to carry out these functions.
	Brazil, Colombia, Nicaragua, Peru
Medium	Policies, laws, and standards exist that regulate the supply of medicines; however, they are not suitably observed, because of a lack of public institutionalization. The responsible departments or units are not provided with the resources to carry out these functions.
	Bolivia, Dominican Republic, El Salvador, Guatemala, Honduras, Mexico, Panama
Low	Policies may exist, but no laws and standards regulate the supply of medicines. For example, no price controls or facility certifications exist. Public institutionalization for regulation of medicine supply does not exist, nor is it required.
	None

• **High-accuracy and timely information systems:** Five countries (Bolivia, Brazil, Dominican Republic, Nicaragua, and Peru) were reported to have timely and accurate information systems for the decision-making process. These countries have information about availability at the health facility level and, by aggregation, in the intermediate and central levels. In El Salvador and Mexico, the existence of information systems was reported, but these still do not generate useful information for decision making. In four countries (Colombia, Guatemala, Honduras, and Panama), no information systems have been developed for the management of medicine supplies.

Table 8. Information Systems

High accuracy and timeliness

An information system (public or private) offers timely and accurate information to decision makers, at least in regard to consumption and stock availability at the health facility level and, by aggregation, at the national level.

Bolivia, Brazil, Dominican Republic, Nicaragua, Peru

Low accuracy and timeliness

A designed and implemented information system exists (public or private), but the information is not useful for decision making because of its lack of timeliness and accuracy. The most accurate information that can be used is from the departmental or central warehouses.

El Salvador, Mexico

Nonexistent

No information system (public or private) offers timely and accurate information to decision makers, at least in regard to consumption and stock availability at the health facility level and, by aggregation, at the national level.

Colombia, Guatamala, Honduras, Panama

• Occasional stock-outs: In seven countries (Bolivia, Brazil, Colombia, El Salvador, Guatemala, Nicaragua, and Peru), occasional stock-outs are reported⁴, and in two more (Honduras and Mexico), continuous stock-outs. These results cannot be entirely attributable to inefficiencies in the supply chain. Even with efficient procedures for planning, purchase, and distribution, the high levels of stock-outs could result from, for example, insufficient financing to cover what is needed. Only one country (Dominican Republic) reported a continuous supply of medicines.

_

⁴ An occasional stock-out is defined as a stock-out of essential medicines for chronic diseases and medicines used by DCPs for less than five days per month during the past 12 months in health facilities.

Table 9. Stock-outs

Continuous supply Records in the information system show (at least during the past 12 months) that in the health facilities there is an uninterrupted supply of essential medicines for chronic diseases and medicines used for disease control programs. Dominican Republic Occasional stock-outs Records in the information system show (at least during the past 12 months) occasional stock-outs (less than 5 days per month) in the health facilities of essential medicines for chronic diseases and medicines used by disease control programs. Boliva, Brazil, Colombia, El Salvador, Guatemala, Nicaragua, Peru Continuous stock-Records in the information system show (at least during the past 12 outs months) continuous stock-outs (more than 10 days per month) of essential medicines for chronic diseases and medicines used by disease control programs in health facilities. Honduras, Mexico

• No accurate estimation of operating costs: The operating costs of the supply chain are not available in 6 of the 11 countries (Colombia, Dominican Republic, Honduras, Mexico, Nicaragua, and Panama). In two countries that had primary or secondary information⁵ (Guatemala and Peru), the cost was categorized as "high" in accordance with international references (a cost of storage and transport higher than 20% of product value). In the three remaining countries (Bolivia, Brazil, and El Salvador), the cost was categorized as medium (between 10% and 20% of the product value). None of the countries that had information estimated their distribution costs under 10% of the product value.

_

⁵ Inferences derived from the study John Snow Inc. Getting products to people: the JSI framework for integrated supply chain management in public health. Arlington, VA: John Snow Inc.; 2012 Jan.

Table 10. Cost

Low	Logistics costs (storage and transport) are less than 10% of product values.
	None
Medium	Logistics costs (storage and transport) are between 10% and 20% of product values.
	Bolivia, Brazil, El Salvador
High	Logistics costs (storage and transport) are greater than 20% of product values.
	Guatemala, Peru
Not available	
	Colombia, Dominican Republic, Honduras, Mexico, Nicaragua, Panama

ANALYSIS AND DISCUSSION

Diverse modalities of supply chain organization and functionality exist in the region. Their organization depends on the particular situation in each country: political, legal, and regulatory framework; geographical conditions; and sectoral reform processes, among others. Therefore, no universal or ideal *recipe* exists for improving the performance of supply chains. The countries that have begun reforms, or have proposed to do so, must, nevertheless, document the current situation, familiarize themselves with the experiences of other countries, and monitor the impact of the transformations in the availability of medicines, operational costs, and access to useful information for decision making.

To develop this study, the ASLAL has proposed a taxonomic system for the characterization of supply chains, and instruments and methodologies for the collection of data. This will allow the Alliance and other participants to monitor the changes in the systems and familiarize themselves with their implications using a standardized methodology.

The results presented in this report, for the first time, characterize the supply chains using standardized criteria. The description of the current situation (at the end of 2014) will help monitor the changes produced by the ongoing reforms and, if solid methodological tools are available in the future, establish a correlation between characteristics and efficiency.

This report, of limited circulation, is directed at technicians specialized in this field and participants responsible for transformations in medicine supply chains. Given that this methodology is still in the process of development and fine-tuning, comments and suggestions are welcome.⁶

-

⁶ Edgar Barillas: <u>ebarillas@msh.org</u>

ANNEX 1. DATA COLLECTION INSTRUMENT

Characteristics	Variable 1	Variable 2	Variable 3	Variable 4		
Institutional affiliation	Public operators	Private operators	Mixed	Private pharmacy		
	All or most of the supply chain operators are State institutions.	Although funding is public, all or most operators are private, contracted agents.	Public operators are responsible for some functions (storage, for example), while other private operators are responsible for others.	All of the medicines financed by private operadispensed from private pharmacies.		erators and
Concentration	Centralized	Decentralized	Mixed	Function	Central	Decentralized
of functions				Programming		
coordinates and distribution to centralized, purchases, customs clearance and storage, and transport to the periphery (region or department). and distribution to centralized, the regions/ the regions/ direct, from departmental/regional distributed to level. If it is mixed following bo the deconcer	The central level	Purchases, storage.	Purchases can be	Purchasing		
	coordinates purchases, customs clearance and storage, and transport to the		centralized, but delivery to the regions/departments is	Quality control		
				Storage		
		departmental/regional	distributed to health facilities. If it is mixed, complete the	Responsibility for transport (centers to dept./region)		
	following box characterizing the deconcentration of functions. →	Responsibility for transport to facilities				
Integration	Integrated	Vertical	Mixed	Function	Integrated	Vertical
				Programming		
	Medicines and	Medicines and	Some disease control	Purchasing		
	supplies for disease	supplies for disease	programs have been	Quality control		
	control programs	control programs (TB,	integrated into a single	Storage		
	(TB, HIV) and noncommunicable pathologies (chronic)	HIV) and noncommunicable pathologies (chronic) use different	system, whereas others keep their own warehouses, inventory management, and	Responsibility for transport (centers to dept./region)		
	use the same mechanisms of storage, inventory management, and transport.	mechanisms of storage, inventory management, and transport.	transport. If it is mixed, complete the following box characterizing the integrated functions. →	Responsibility for transport to facilities		

Characteristics	Variable 1	Variable 2	Variable 3	Variable 4	
Model	Direct delivery or purchase The products are bought at the regional, district, municipal, or other lower levels and the products are collected by lower levels or delivered to regional, district, or municipal warehouses under the administration of the public sector.	Primary distributor The medicines and supplies are watched over by and distributed from one or various central or peripheral warehouses under administration of a private operator contracted by the public sector.	Central medicine warehouse The medicines and supplies are watched over by and distributed from one or various central warehouses, under administration of the public sector, from which transport to the periphery is coordinated.	If distribution is from a central medical warehouse, identify if the central warehouse transports in its own vehicles (delivery) or if the facilities come to collect (collection).	Delivery Collection
Level of regulation	High Policies, laws, and standards exist that regulate the supply of medicines. For example, price controls, facility certifications, and standardized procedures for the management of supplies exist, and they are observed. Public institutions (departments, units) are provided with the resources to carry out these functions.	Medium There are policies, laws, and standards that regulate the supply of medicines, but, regardless, they are not adequately observed, owing to a lack of public institutionalization. The responsible departments or units are not provided with the resources to complete these functions.	Policies may exist, but no laws and standards regulate the supply of medicines. For example, price controls or facility certifications do not exist. Public institutionalization for regulation of medicine supply does not exist, nor is it required.		

Characteristics	Variable 1	Variable 2	Variable 3	Variable 4
Information system	High accuracy and timeliness An information system (public or private) offers timely and accurate information to decision makers, at least in regard to consumption and stock availability at the health facility level and, by aggregation, at the national level.	Low accuracy and timeliness A designed and implemented information system exists (public or private), but the information is not useful for decision making because of its lack of timeliness and accuracy. The most accurate information that can be used is from the departmental or central warehouses.	No information system (public or private) offers timely and accurate information to decision makers, at least in regard to consumption and stock availability at the health facility level and, by aggregation, at the national level.	
Availability of medicines	Continuous supply Records in the information system show (at least during the past 12 months) that in the health facilities there is an uninterrupted supply of essential medicines for chronic diseases and medicines used for disease control programs.	Occasional stockouts Records in the information system show (at least during the past 12 months) that in the health facilities there are occasional stock-outs (less than five days per month) of essential medicines for chronic diseases and medicines used by disease control programs.	Records in the information system show (at least during the past 12 months) that in the health facilities there are continuous stock-outs (more than 10 days per month) of essential medicines for chronic diseases and medicines used by disease control programs.	

Characteristics	Variable 1	Variable 2	Variable 3	Variable 4
Cost	Low The logistics costs (storage and transport) are less than 10% of product values. Source:	Medium The logistics costs (storage and transport) are between 10% and 20% of product values. Source:	High The logistics costs (storage and transport) are more than 20% of product values. Source:	Not available No logistics operational cost estimates exist.

Comments: